Skip to main content
SpringerLink
Log in

Anterior pituitary hormone replacement therapy—a clinical review

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

This clinical review summarizes current approaches to diagnosis and treatment of anterior pituitary hormone deficiency. The diagnostic value of endocrine function tests and replacement strategies for hydrocortisone, thyroxine, sex steroids, and growth hormone replacement are reviewed. Female androgen deficiency syndrome and the current role of DHEA and testosterone replacement in women are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Regal M, Paramo C, Sierra SM, Garcia-Mayor RV (2001) Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin Endocrinol (Oxf) 55:735–740

    CAS  Google Scholar 

  2. Bondanelli M, Ambrosio MR, Zatelli MC, De Marinis L, degli Uberti EC (2005) Hypopituitarism after traumatic brain injury. Eur J Endocrinol 152:679–691

    PubMed  CAS  Google Scholar 

  3. Aimaretti G, Ambrosio MR, Di Somma C, Gasperi M, Cannavo S, Scaroni C et al (2005) Hypopituitarism induced by traumatic brain injury in the transition phase. J Endocrinol Invest 28:984–989

    PubMed  CAS  Google Scholar 

  4. Ghigo E, Masel B, Aimaretti G, Leon-Carrion J, Casanueva FF, Dominguez-Morales MR et al (2005) Consensus guidelines on screening for hypopituitarism following traumatic brain injury. Brain Inj 19:711–724

    PubMed  CAS  Google Scholar 

  5. Schneider HJ, Schneider M, Saller B, Petersenn S, Uhr M, Husemann B et al (2006) Prevalence of anterior pituitary insufficiency 3 and 12 months after traumatic brain injury. Eur J Endocrinol 154:259–265

    PubMed  CAS  Google Scholar 

  6. Schneider M, Schneider HJ, Stalla GK (2005) Anterior pituitary hormone abnormalities following traumatic brain injury. J Neurotrauma 22:937–946

    PubMed  Google Scholar 

  7. Endert E, Ouwehand A, Fliers E, Prummel MF, Wiersinga WM (2005) Establishment of reference values for endocrine tests. Part IV: adrenal insufficiency. Neth J Med 63:435–443

    PubMed  CAS  Google Scholar 

  8. Arlt W, Allolio B (2003) Adrenal insufficiency. Lancet 361:1881–1893

    PubMed  CAS  Google Scholar 

  9. Schmidt IL, Lahner H, Mann K, Petersenn S (2003) Diagnosis of adrenal insufficiency: evaluation of the corticotropin-releasing hormone test and Basal serum cortisol in comparison to the insulin tolerance test in patients with hypothalamic–pituitary–adrenal disease. J Clin Endocrinol Metab 88:4193–4198

    PubMed  CAS  Google Scholar 

  10. van Aken MO, Lamberts SW (2005) Diagnosis and treatment of hypopituitarism: an update. Pituitary 8:183–191

    PubMed  Google Scholar 

  11. Dullaart RP, Pasterkamp SH, Beentjes JA, Sluiter WJ (1999) Evaluation of adrenal function in patients with hypothalamic and pituitary disorders: comparison of serum cortisol, urinary free cortisol and the human-corticotrophin releasing hormone test with the insulin tolerance test. Clin Endocrinol (Oxf) 50:465–471

    CAS  Google Scholar 

  12. Agha A, Tomlinson JW, Clark PM, Holder G, Stewart PM (2006) The long-term predictive accuracy of the short synacthen (corticotropin) stimulation test for assessment of the hypothalamic–pituitary–adrenal axis. J Clin Endocrinol Metab 91:43–47

    PubMed  CAS  Google Scholar 

  13. Reynolds RM, Stewart PM, Seckl JR, Padfield PL (2006) Assessing the HPA axis in patients with pituitary disease: a UK survey. Clin Endocrinol (Oxf) 64:82–85

    Google Scholar 

  14. Dorin RI, Qualls CR, Crapo LM (2003) Diagnosis of adrenal insufficiency. Ann Intern Med 139:194–204

    PubMed  Google Scholar 

  15. Gleeson HK, Walker BR, Seckl JR, Padfield PL (2003) Ten years on: Safety of short synacthen tests in assessing adrenocorticotropin deficiency in clinical practice. J Clin Endocrinol Metab 88:2106–2111

    PubMed  CAS  Google Scholar 

  16. Klose M, Lange M, Kosteljanetz M, Poulsgaard L, Feldt-Rasmussen U (2005) Adrenocortical insufficiency after pituitary surgery: an audit of the reliability of the conventional short synacthen test. Clin Endocrinol (Oxf) 63:499–505

    CAS  Google Scholar 

  17. Widmer IE, Puder JJ, Konig C, Pargger H, Zerkowski HR, Girard J et al (2005) Cortisol response in relation to the severity of stress and illness. J Clin Endocrinol Metab 90:4579–4586

    PubMed  CAS  Google Scholar 

  18. Maghnie M, Uga E, Temporini F, Di Iorgi N, Secco A, Tinelli C et al (2005) Evaluation of adrenal function in patients with growth hormone deficiency and hypothalamic–pituitary disorders: comparison between insulin-induced hypoglycemia, low-dose ACTH, standard ACTH and CRH stimulation tests. Eur J Endocrinol 152:735–741

    PubMed  CAS  Google Scholar 

  19. Lamberts SW, de Herder WW, van der Lely AJ (1998) Pituitary insufficiency. Lancet 352:127–134

    PubMed  CAS  Google Scholar 

  20. Peacey SR, Guo CY, Robinson AM, Price A, Giles MA, Eastell R et al (1997) Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol (Oxf) 46:255–261

    CAS  Google Scholar 

  21. Howlett TA (1997) An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol (Oxf) 46:263–268

    CAS  Google Scholar 

  22. Peacey SR, Yuan Guo C, Eastell R, Weetman AP (1999) Optimization of glucocorticoid replacement therapy: the long-term effect on bone mineral density. Clin Endocrinol (Oxf) 50:815–817

    CAS  Google Scholar 

  23. Heureux F, Maiter D, Boutsen Y, Devogelaer JP, Jamart J, Donckier J (2000) Evaluation of corticosteroid replacement therapy and its effect on bones in Addison’s disease. Ann Endocrinol (Paris) 61:179–183

    CAS  Google Scholar 

  24. al-Shoumer KA, Beshyah SA, Niththyananthan R, Johnston DG (1995) Effect of glucocorticoid replacement therapy on glucose tolerance and intermediary metabolites in hypopituitary adults. Clin Endocrinol (Oxf) 42:85–90

    CAS  Google Scholar 

  25. McConnell EM, Bell PM, Hadden DR, McCance DR, Sheridan B, Atkinson AB (2001) Prevalence of diabetes and impaired glucose tolerance in adult hypopituitarism on low dose oral hydrocortisone replacement therapy. Clin Endocrinol (Oxf) 54:593–599

    CAS  Google Scholar 

  26. McConnell EM, Bell PM, Ennis C, Hadden DR, McCance DR, Sheridan B et al (2002) Effects of low-dose oral hydrocortisone replacement versus short-term reproduction of physiological serum cortisol concentrations on insulin action in adult-onset hypopituitarism. Clin Endocrinol (Oxf) 56:195–201

    CAS  Google Scholar 

  27. Elhadd TA, Abdu TA, Clayton R (2001) Hypopituitarism and atherosclerosis. Ann Med 33:477–485

    PubMed  CAS  Google Scholar 

  28. Derendorf H, Mollmann H, Barth J, Mollmann C, Tunn S, Krieg M (1991) Pharmacokinetics and oral bioavailability of hydrocortisone. J Clin Pharmacol 31:473–476

    PubMed  CAS  Google Scholar 

  29. Charmandari E, Johnston A, Brook CG, Hindmarsh PC (2001) Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Endocrinol 169:65–70

    PubMed  CAS  Google Scholar 

  30. Purnell JQ, Brandon DD, Isabelle LM, Loriaux DL, Samuels MH (2004) Association of 24-hour cortisol production rates, cortisol-binding globulin, and plasma-free cortisol levels with body composition, leptin levels, and aging in adult men and women. J Clin Endocrinol Metab 89:281–287

    PubMed  CAS  Google Scholar 

  31. Kraan GP, Dullaart RP, Pratt JJ, Wolthers BG, de Bruin R (1997) Kinetics of intravenously dosed cortisol in four men. Consequences for calculation of the plasma cortisol production rate. J Steroid Biochem Mol Biol 63:139–146

    PubMed  CAS  Google Scholar 

  32. Charmandari E, Hindmarsh PC, Johnston A, Brook CG (2001) Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty. J Clin Endocrinol Metab 86:2701–2708

    PubMed  CAS  Google Scholar 

  33. Groschl M, Rauh M, Dorr HG (2002) Cortisol and 17-hydroxyprogesterone kinetics in saliva after oral administration of hydrocortisone in children and young adolescents with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 87:1200–1204

    PubMed  CAS  Google Scholar 

  34. Al-Shoumer KA, Ali K, Anyaoku V, Niththyananthan R, Johnston DG (1996) Overnight metabolic fuel deficiency in patients treated conventionally for hypopituitarism. Clin Endocrinol (Oxf) 45:171–178

    CAS  Google Scholar 

  35. DeVile CJ, Stanhope R (1997) Hydrocortisone replacement therapy in children and adolescents with hypopituitarism. Clin Endocrinol (Oxf) 47:37–41

    CAS  Google Scholar 

  36. Crown A, Lightman S (2005) Why is the management of glucocorticoid deficiency still controversial: a review of the literature. Clin Endocrinol (Oxf) 63:483–492

    CAS  Google Scholar 

  37. Arlt W, Rosenthal C, Hahner S, Allolio B (2006) Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clin Endocrinol (Oxf) 64:384–389

    CAS  Google Scholar 

  38. Stewart PM, Toogood AA, Tomlinson JW (2001) Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle. Horm Res 56(Suppl 1):1–6

    PubMed  CAS  Google Scholar 

  39. Swords FM, Carroll PV, Kisalu J, Wood PJ, Taylor NF, Monson JP (2003) The effects of growth hormone deficiency and replacement on glucocorticoid exposure in hypopituitary patients on cortisone acetate and hydrocortisone replacement. Clin Endocrinol (Oxf) 59:613–620

    CAS  Google Scholar 

  40. Miller KK, Sesmilo G, Schiller A, Schoenfeld D, Burton S, Klibanski A (2001) Androgen deficiency in women with hypopituitarism. J Clin Endocrinol Metab 86:561–567

    PubMed  CAS  Google Scholar 

  41. Beentjes JA, Kerstens MN, Dullaart RP (2001) Effects of growth hormone replacement on cortisol metabolism in hypopituitary patients treated with cortisone acetate. Scand J Clin Lab Invest 61:277–286

    PubMed  CAS  Google Scholar 

  42. Toogood AA, Taylor NF, Shalet SM, Monson JP (2000) Modulation of cortisol metabolism by low-dose growth hormone replacement in elderly hypopituitary patients. J Clin Endocrinol Metab 85:1727–1730

    PubMed  CAS  Google Scholar 

  43. Tschop M, Lahner H, Feldmeier H, Grasberger H, Morrison KM, Janssen OE et al (2000) Effects of growth hormone replacement therapy on levels of cortisol and cortisol-binding globulin in hypopituitary adults. Eur J Endocrinol 143:769–773

    PubMed  CAS  Google Scholar 

  44. Weaver JU, Thaventhiran L, Noonan K, Burrin JM, Taylor NF, Norman MR et al (1994) The effect of growth hormone replacement on cortisol metabolism and glucocorticoid sensitivity in hypopituitary adults. Clin Endocrinol (Oxf) 41:639–648

    CAS  Google Scholar 

  45. Paulsen SK, Pedersen SB, Jorgensen JO, Fisker S, Christiansen JS, Flyvbjerg A et al (2006) Growth hormone (GH) substitution in GH-deficient patients inhibits 11β-hydroxysteroid dehydrogenase type 1 messenger ribonucleic acid expression in adipose tissue. J Clin Endocrinol Metab 91:1093–1098

    PubMed  CAS  Google Scholar 

  46. Lindsay JR, Nieman LK (2005) The hypothalamic–pituitary–adrenal axis in pregnancy: challenges in disease detection and treatment. Endocr Rev 26:775–799

    PubMed  CAS  Google Scholar 

  47. Flemming TG, Kristensen LO (1999) Quality of self-care in patients on replacement therapy with hydrocortisone. J Intern Med 246:497–501

    PubMed  CAS  Google Scholar 

  48. Ladenson PW, Singer PA, Ain KB, Bagchi N, Bigos ST, Levy EG et al (2000) American Thyroid Association guidelines for detection of thyroid dysfunction. Arch Intern Med 160:1573–1575

    PubMed  CAS  Google Scholar 

  49. Roberts CG, Ladenson PW (2004) Hypothyroidism. Lancet 363:793–803

    PubMed  CAS  Google Scholar 

  50. Wardle CA, Fraser WD, Squire CR (2001) Pitfalls in the use of thyrotropin concentration as a first-line thyroid-function test. Lancet 357:1013–1014

    PubMed  CAS  Google Scholar 

  51. Ferretti E, Persani L, Jaffrain-Rea ML, Giambona S, Tamburrano G, Beck-Peccoz P (1999) Evaluation of the adequacy of levothyroxine replacement therapy in patients with central hypothyroidism. J Clin Endocrinol Metab 84:924–929

    PubMed  CAS  Google Scholar 

  52. Shimon I, Cohen O, Lubetsky A, Olchovsky D (2002) Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism. Thyroid 12:823–827

    PubMed  CAS  Google Scholar 

  53. Alexopoulou O, Beguin C, De Nayer P, Maiter D (2004) Clinical and hormonal characteristics of central hypothyroidism at diagnosis and during follow-up in adult patients. Eur J Endocrinol 150:1–8

    PubMed  CAS  Google Scholar 

  54. Hartoft-Nielsen ML, Lange M, Rasmussen AK, Scherer S, Zimmermann-Belsing T, Feldt-Rasmussen U (2004) Thyrotropin-releasing hormone stimulation test in patients with pituitary pathology. Horm Res 61:53–57

    PubMed  CAS  Google Scholar 

  55. Mehta A, Hindmarsh PC, Stanhope RG, Brain CE, Preece MA, Dattani MT (2003) Is the thyrotropin-releasing hormone test necessary in the diagnosis of central hypothyroidism in children. J Clin Endocrinol Metab 88:5696–5703

    PubMed  CAS  Google Scholar 

  56. Persani L, Ferretti E, Borgato S, Faglia G, Beck-Peccoz P (2000) Circulating thyrotropin bioactivity in sporadic central hypothyroidism. J Clin Endocrinol Metab 85:3631–3635

    PubMed  CAS  Google Scholar 

  57. Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ Jr (1999) Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med 340:424–429

    PubMed  CAS  Google Scholar 

  58. Sawka AM, Gerstein HC, Marriott MJ, MacQueen GM, Joffe RT (2003) Does a combination regimen of thyroxine (T4) and 3,5,3′-triiodothyronine improve depressive symptoms better than T4 alone in patients with hypothyroidism? Results of a double-blind, randomized, controlled trial. J Clin Endocrinol Metab 88:4551–4555

    PubMed  CAS  Google Scholar 

  59. Walsh JP, Shiels L, Lim EM, Bhagat CI, Ward LC, Stuckey BG et al (2003) Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism. J Clin Endocrinol Metab 88:4543–4550

    PubMed  CAS  Google Scholar 

  60. Clyde PW, Harari AE, Getka EJ, Shakir KM (2003) Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. JAMA 290:2952–2958

    PubMed  CAS  Google Scholar 

  61. Siegmund W, Spieker K, Weike AI, Giessmann T, Modess C, Dabers T et al (2004) Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14: 1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism. Clin Endocrinol (Oxf) 60:750–757

    CAS  Google Scholar 

  62. Escobar-Morreale HF, Botella-Carretero JI, Gomez-Bueno M, Galan JM, Barrios V, Sancho J (2005) Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing l-thyroxine plus liothyronine with l-thyroxine alone. Ann Intern Med 142:412–424

    PubMed  CAS  Google Scholar 

  63. Appelhof BC, Fliers E, Wekking EM, Schene AH, Huyser J, Tijssen JG et al (2005) Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind, randomized, controlled clinical trial. J Clin Endocrinol Metab 90:2666–2674

    PubMed  CAS  Google Scholar 

  64. Wiersinga WM (2001) Thyroid hormone replacement therapy. Horm Res 56(Suppl 1):74–81

    PubMed  CAS  Google Scholar 

  65. Andersen S, Pedersen KM, Bruun NH, Laurberg P (2002) Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab 87:1068–1072

    PubMed  CAS  Google Scholar 

  66. Toft AD (2001) Clinical practice. Subclinical hyperthyroidism. N Engl J Med 345:512–516

    PubMed  CAS  Google Scholar 

  67. Auer J, Scheibner P, Mische T, Langsteger W, Eber O, Eber B (2001) Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J 142:838–842

    PubMed  CAS  Google Scholar 

  68. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA (2001) Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 358:861–865

    PubMed  CAS  Google Scholar 

  69. Cooper DS (2001) Clinical practice. Subclinical hypothyroidism. N Engl J Med 345:260–265

    PubMed  CAS  Google Scholar 

  70. Smallridge RC, Ladenson PW (2001) Hypothyroidism in pregnancy: consequences to neonatal health. J Clin Endocrinol Metab 86:2349–2353

    PubMed  CAS  Google Scholar 

  71. Arafah BM (2001) Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med 344:1743–1749

    PubMed  CAS  Google Scholar 

  72. Jorgensen JO, Ovesen P, Juul A, Hansen TK, Skakkebaek NE, Christiansen JS (1999) Impact of growth hormone administration on other hormonal axes. Horm Res 51(Suppl 3):121–126

    PubMed  CAS  Google Scholar 

  73. Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society (2001) J Clin Endocrinol Metab 86:1868–1870

  74. Porretti S, Giavoli C, Ronchi C, Lombardi G, Zaccaria M, Valle D et al (2002) Recombinant human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients: when does L-T(4) therapy become mandatory? J Clin Endocrinol Metab 87:2042–2045

    PubMed  CAS  Google Scholar 

  75. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS et al (2006) Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 91:1995–2010

    PubMed  CAS  Google Scholar 

  76. Nieschlag E, Behre HM, Bouchard P, Corrales JJ, Jones TH, Stalla GK et al (2004) Testosterone replacement therapy: current trends and future directions. Hum Reprod Update 10:409–419

    PubMed  CAS  Google Scholar 

  77. Vermeulen A (2004) Reflections concerning biochemical parameters of androgenicity. Aging Male 7:280–289

    PubMed  CAS  Google Scholar 

  78. Kaufman JM, Vermeulen A (2005) The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 26:833–876

    PubMed  CAS  Google Scholar 

  79. Vermeulen A, Verdonck L, Kaufman JM (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666–3672

    PubMed  CAS  Google Scholar 

  80. Howell S, Shalet S (2001) Testosterone deficiency and replacement. Horm Res 56(Suppl 1):86–92

    PubMed  CAS  Google Scholar 

  81. Wang C, Catlin DH, Starcevic B, Leung A, DiStefano E, Lucas G et al (2004) Testosterone metabolic clearance and production rates determined by stable isotope dilution/tandem mass spectrometry in normal men: influence of ethnicity and age. J Clin Endocrinol Metab 89:2936–2941

    PubMed  CAS  Google Scholar 

  82. Vierhapper H, Nowotny P, Waldhausl W (2003) Reduced production rates of testosterone and dihydrotestosterone in healthy men treated with rosiglitazone. Metabolism 52:230–232

    PubMed  CAS  Google Scholar 

  83. Vierhapper H, Nowotny P, Waldhausl W (1998) Unchanged testosterone production rates in growth hormone-treated healthy men. J Clin Endocrinol Metab 83:3735–3736

    PubMed  CAS  Google Scholar 

  84. Morales A, Lunenfeld B (2002) Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male. Aging Male 5:74–86

    PubMed  CAS  Google Scholar 

  85. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ et al (2005) Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl 28:125–127

    PubMed  CAS  Google Scholar 

  86. Rhoden EL, Morgentaler A (2004) Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 350:482–492

    PubMed  CAS  Google Scholar 

  87. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms (2005) Ann Intern Med 142:1003–1013

  88. Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force (2005) Ann Intern Med 142:855–860

  89. Farquhar CM, Marjoribanks J, Lethaby A, Lamberts Q, Suckling JA. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2005:CD004143

  90. Hickey M, Davis SR, Sturdee DW (2005) Treatment of menopausal symptoms: what shall we do now? Lancet 366:409–421

    PubMed  Google Scholar 

  91. Skouby SO, Al-Azzawi F, Barlow D, Calaf-Alsina Erdogan Ertungealp J, Gompel A, Graziottin A et al (2005) Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas 51:8–14

    PubMed  Google Scholar 

  92. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS et al (2001) Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357:425–431

    PubMed  CAS  Google Scholar 

  93. Mah PM, Webster J, Jonsson P, Feldt-Rasmussen U, Koltowska-Haggstrom M, Ross RJ (2005) Estrogen replacement in women of fertile years with hypopituitarism. J Clin Endocrinol Metab 90:5964–5969

    PubMed  CAS  Google Scholar 

  94. Menon DV, Vongpatanasin W (2006) Effects of transdermal estrogen replacement therapy on cardiovascular risk factors. Treat Endocrinol 5:37–51

    PubMed  CAS  Google Scholar 

  95. Leung KC, Johannsson G, Leong GM, Ho KK (2004) Estrogen regulation of growth hormone action. Endocr Rev 25:693–721

    PubMed  CAS  Google Scholar 

  96. Lethaby A, Farquhar C, Sarkis A, Roberts H, Jepson R, Barlow D. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2000:CD000402

  97. Elmlinger MW, Kuhnel W, Wormstall H, Doller PC (2005) Reference intervals for testosterone, androstenedione and SHBG levels in healthy females and males from birth until old age. Clin Lab 51:625–632

    PubMed  CAS  Google Scholar 

  98. Bachmann G, Bancroft J, Braunstein G, Burger H, Davis S, Dennerstein L et al (2002) Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 77:660–665

    PubMed  Google Scholar 

  99. Santoro N, Torrens J, Crawford S, Allsworth JE, Finkelstein JS, Gold EB et al (2005) Correlates of circulating androgens in mid-life women: the study of women’s health across the nation. J Clin Endocrinol Metab 90:4836–4845

    PubMed  CAS  Google Scholar 

  100. Bhasin S (2005) Female androgen deficiency syndrome—an unproven hypothesis. J Clin Endocrinol Metab 90:4970–4972

    PubMed  CAS  Google Scholar 

  101. Basson R (2006) Clinical practice. Sexual desire and arousal disorders in women. N Engl J Med 354:1497–1506

    PubMed  CAS  Google Scholar 

  102. Arlt W, Callies F, van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M et al (1999) Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 341:1013–1020

    PubMed  CAS  Google Scholar 

  103. Gebre-Medhin G, Husebye ES, Mallmin H, Helstrom L, Berne C, Karlsson FA et al (2000) Oral dehydroepiandrosterone (DHEA) replacement therapy in women with Addison’s disease. Clin Endocrinol (Oxf) 52:775–780

    CAS  Google Scholar 

  104. Hunt PJ, Gurnell EM, Huppert FA, Richards C, Prevost AT, Wass JA et al (2000) Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison’s disease in a randomized, double blind trial. J Clin Endocrinol Metab 85:4650–4656

    PubMed  CAS  Google Scholar 

  105. Gurnell EM, Chatterjee VK (2001) Dehydroepiandrosterone replacement therapy. Eur J Endocrinol 145:103–106

    PubMed  CAS  Google Scholar 

  106. Johannsson G, Burman P, Wiren L, Engstrom BE, Nilsson AG, Ottosson M et al (2002) Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J Clin Endocrinol Metab 87:2046–2052

    PubMed  CAS  Google Scholar 

  107. Parasrampuria J, Schwartz K, Petesch R (1998) Quality control of dehydroepiandrosterone dietary supplement products. JAMA 280(18):1565

    PubMed  CAS  Google Scholar 

  108. Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch A et al (2005) Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 105:944–952

    PubMed  CAS  Google Scholar 

  109. Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA et al (2005) Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 165:1582–1589

    PubMed  CAS  Google Scholar 

  110. Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S et al (2005) Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 90:5226–5233

    PubMed  CAS  Google Scholar 

  111. Davis SR, van der Mooren MJ, van Lunsen RH, Lopes P, Ribot J, Rees M et al (2006) Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause 13:387–396

    PubMed  Google Scholar 

  112. Miller KK, Biller BM, Beauregard C, Lipman JG, Jones J, Schoenfeld D et al (2006) Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 91:1683–1690

    PubMed  CAS  Google Scholar 

  113. Shames D, Monroe SE, Davis D, Soule L (2007) Regulatory perspective on clinical trials and end points for female sexual dysfunction, in particular, hypoactive sexual desire disorder: formulating recommendations in an environment of evolving clinical science. Int J Impot Res 19(1):30–36

    PubMed  CAS  Google Scholar 

  114. The role of testosterone therapy in postmenopausal women: position statement of The North American Menopause Society (2005) Menopause 12:496–511; quiz 649

    Google Scholar 

  115. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency (1998) J Clin Endocrinol Metab 83:379–381

    Google Scholar 

  116. Gharib H, Cook DM, Saenger PH, Bengtsson BA, Feld S, Nippoldt TB et al (2003) American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children—2003 update. Endocr Pract 9:64–76

    PubMed  Google Scholar 

  117. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Shalet SM, Vance ML et al (2006) Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 91:1621–1634

    PubMed  CAS  Google Scholar 

  118. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society (2000) J Clin Endocrinol Metab 85:3990–3993

  119. Wilson TA, Rose SR, Cohen P, Rogol AD, Backeljauw P, Brown R et al (2003) Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J Pediatr 143:415–421

    PubMed  Google Scholar 

  120. Clayton PE, Cuneo RC, Juul A, Monson JP, Shalet SM, Tauber M (2005) Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol 152:165–170

    PubMed  CAS  Google Scholar 

  121. Veldhuis JD, Roemmich JN, Richmond EJ, Bowers CY (2006) Somatotropic and gonadotropic axes linkages in infancy, childhood, and the puberty–adult transition. Endocr Rev 27:101–140

    PubMed  CAS  Google Scholar 

  122. Aimaretti G, Corneli G, Razzore P, Bellone S, Baffoni C, Arvat E et al (1998) Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults. J Clin Endocrinol Metab 83:1615–1618

    PubMed  CAS  Google Scholar 

  123. Biller BM, Samuels MH, Zagar A, Cook DM, Arafah BM, Bonert V et al (2002) Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 87:2067–2079

    PubMed  CAS  Google Scholar 

  124. Abs R (2003) Update on the diagnosis of GH deficiency in adults. Eur J Endocrinol 148(Suppl 2):S3–S8

    PubMed  CAS  Google Scholar 

  125. Bonert VS, Elashoff JD, Barnett P, Melmed S (2004) Body mass index determines evoked growth hormone (GH) responsiveness in normal healthy male subjects: diagnostic caveat for adult GH deficiency. J Clin Endocrinol Metab 89:3397–3401

    PubMed  CAS  Google Scholar 

  126. Qu XD, Gaw Gonzalo IT, Al Sayed MY, Cohan P, Christenson PD, Swerdloff RS et al (2005) Influence of body mass index and gender on growth hormone (GH) responses to GH-releasing hormone plus arginine and insulin tolerance tests. J Clin Endocrinol Metab 90:1563–1569

    PubMed  CAS  Google Scholar 

  127. Corneli G, Di Somma C, Baldelli R, Rovere S, Gasco V, Croce CG et al (2005) The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol 153:257–264

    PubMed  CAS  Google Scholar 

  128. Aimaretti G, Corneli G, Baldelli R, Di Somma C, Gasco V, Durante C et al (2003) Diagnostic reliability of a single IGF-I measurement in 237 adults with total anterior hypopituitarism and severe GH deficiency. Clin Endocrinol (Oxf) 59:56–61

    CAS  Google Scholar 

  129. Hartman ML, Crowe BJ, Biller BM, Ho KK, Clemmons DR, Chipman JJ (2002) Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab 87:477–485

    PubMed  CAS  Google Scholar 

  130. Woodhouse LJ, Mukherjee A, Shalet SM, Ezzat S (2006) The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults. Endocr Rev 27:287–317

    PubMed  CAS  Google Scholar 

  131. Brabant G, von zur Muhlen A, Wuster C, Ranke MB, Kratzsch J, Kiess W et al (2003) Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 60:53–60

    PubMed  CAS  Google Scholar 

  132. Jostel A, Mukherjee A, Alenfall J, Smethurst L, Shalet SM (2005) A new sustained-release preparation of human growth hormone and its pharmacokinetic, pharmacodynamic and safety profile. Clin Endocrinol (Oxf) 62:623–627

    CAS  Google Scholar 

  133. Hoffman AR, Biller BM, Cook D, Baptista J, Silverman BL, Dao L et al (2005) Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency. J Clin Endocrinol Metab 90:6431–6440

    PubMed  CAS  Google Scholar 

  134. Kehely A, Bates PC, Frewer P, Birkett M, Blum WF, Mamessier P et al (2002) Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a comparison of two dosage algorithms. J Clin Endocrinol Metab 87:1974–1979

    PubMed  CAS  Google Scholar 

  135. Hoffman AR, Strasburger CJ, Zagar A, Blum WF, Kehely A, Hartman ML (2004) Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing. J Clin Endocrinol Metab 89:3224–3233

    PubMed  CAS  Google Scholar 

  136. Bengtsson BA, Abs R, Bennmarker H, Monson JP, Feldt-Rasmussen U, Hernberg-Stahl E et al (1999) The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board. J Clin Endocrinol Metab 84:3929–3935

    PubMed  CAS  Google Scholar 

  137. Gotherstrom G, Svensson J, Koranyi J, Alpsten M, Bosaeus I, Bengtsson B et al (2001) A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 86:4657–4665

    PubMed  CAS  Google Scholar 

  138. Murray RD, Howell SJ, Lissett CA, Shalet SM (2000) Pre-treatment IGF-I level is the major determinant of GH dosage in adult GH deficiency. Clin Endocrinol (Oxf) 52:537–542

    CAS  Google Scholar 

  139. Abs R, Bengtsson BA, Hernberg-Stahl E, Monson JP, Tauber JP, Wilton P et al (1999) GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol (Oxf) 50:703–713

    CAS  Google Scholar 

  140. Underwood LE, Attie KM, Baptista J (2003) Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study. J Clin Endocrinol Metab 88:5273–5280

    PubMed  CAS  Google Scholar 

  141. Feldt-Rasmussen U, Wilton P, Jonsson P (2004) Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults. Growth Horm IGF Res 14(Suppl A):S51–58

    PubMed  CAS  Google Scholar 

  142. Carroll PV, Christ ER, Bengtsson BA, Carlsson L, Christiansen JS, Clemmons D et al (1998) Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 83:382–395

    PubMed  CAS  Google Scholar 

  143. Attanasio AF, Bates PC, Ho KK, Webb SM, Ross RJ, Strasburger CJ et al (2002) Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status—3-year results from the HypoCCS Database. J Clin Endocrinol Metab 87:1600–1606

    PubMed  CAS  Google Scholar 

  144. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P (2004) Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab 89:2192–2199

    PubMed  CAS  Google Scholar 

  145. Svensson J, Stibrant Sunnerhagen K, Johannsson G (2003) Five years of growth hormone replacement therapy in adults: age- and gender-related changes in isometric and isokinetic muscle strength. J Clin Endocrinol Metab 88:2061–2069

    PubMed  CAS  Google Scholar 

  146. Gibney J, Wallace JD, Spinks T, Schnorr L, Ranicar A, Cuneo RC et al (1999) The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab 84:2596–2602

    PubMed  CAS  Google Scholar 

  147. Gotherstrom G, Bengtsson BA, Sunnerhagen KS, Johannsson G, Svensson J (2005) The effects of five-year growth hormone replacement therapy on muscle strength in elderly hypopituitary patients. Clin Endocrinol (Oxf) 62:105–113

    Google Scholar 

  148. Maison P, Chanson P (2003) Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation 108:2648–2652

    PubMed  CAS  Google Scholar 

  149. Drake WM, Howell SJ, Monson JP, Shalet SM (2001) Optimizing gh therapy in adults and children. Endocr Rev 22:425–450

    PubMed  CAS  Google Scholar 

  150. Wuster C, Abs R, Bengtsson BA, Bennmarker H, Feldt-Rasmussen U, Hernberg-Stahl E et al (2001) The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res 16:398–405

    PubMed  CAS  Google Scholar 

  151. Davidson P, Milne R, Chase D, Cooper C (2004) Growth hormone replacement in adults and bone mineral density: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 60:92–98

    CAS  Google Scholar 

  152. Bravenboer N, Holzmann PJ, ter Maaten JC, Stuurman LM, Roos JC, Lips P (2005) Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormone-deficient men. J Bone Miner Res 20:1778–1784

    PubMed  CAS  Google Scholar 

  153. Arwert LI, Roos JC, Lips P, Twisk JW, Manoliu RA, Drent ML (2005) Effects of 10 years of growth hormone (GH) replacement therapy in adult GH-deficient men. Clin Endocrinol (Oxf) 63:310–316

    CAS  Google Scholar 

  154. Hernberg-Stahl E, Luger A, Abs R, Bengtsson BA, Feldt-Rasmussen U, Wilton P et al (2001) Healthcare consumption decreases in parallel with improvements in quality of life during GH replacement in hypopituitary adults with GH deficiency. J Clin Endocrinol Metab 86:5277–5281

    PubMed  CAS  Google Scholar 

  155. Radcliffe DJ, Pliskin JS, Silvers JB, Cuttler L (2004) Growth hormone therapy and quality of life in adults and children. Pharmacoeconomics 22:499–524

    PubMed  CAS  Google Scholar 

  156. Koltowska-Haggstrom M, Hennessy S, Mattsson AF, Monson JP, Kind P (2005) Quality of life assessment of growth hormone deficiency in adults (QoL-AGHDA): comparison of normative reference data for the general population of England and Wales with results for adult hypopituitary patients with growth hormone deficiency. Horm Res 64:46–54

    PubMed  Google Scholar 

  157. Rosilio M, Blum WF, Edwards DJ, Shavrikova EP, Valle D, Lamberts SW et al (2004) Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). J Clin Endocrinol Metab 89:1684–1693

    PubMed  CAS  Google Scholar 

  158. Blum WF, Shavrikova EP, Edwards DJ, Rosilio M, Hartman ML, Marin F et al (2003) Decreased quality of life in adult patients with growth hormone deficiency compared with general populations using the new, validated, self-weighted questionnaire, questions on life satisfaction hypopituitarism module. J Clin Endocrinol Metab 88:4158–4167

    PubMed  CAS  Google Scholar 

  159. Colao A (2004) Cardiovascular effects of growth hormone treatment: potential risks and benefits. Horm Res 62(Suppl 3):42–50

    PubMed  CAS  Google Scholar 

  160. Colao A, Di Somma C, Rota F, Pivonello R, Savanelli MC, Spiezia S et al (2005) Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency. J Clin Endocrinol Metab 90:2056–2062

    PubMed  CAS  Google Scholar 

  161. Colao A, Di Somma C, Cuocolo A, Filippella M, Rota F, Acampa W et al (2004) The severity of growth hormone deficiency correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: an observational, case-control study. J Clin Endocrinol Metab 89:5998–6004

    PubMed  CAS  Google Scholar 

  162. Gola M, Bonadonna S, Doga M, Giustina A (2005) Clinical review: growth hormone and cardiovascular risk factors. J Clin Endocrinol Metab 90:1864–1870

    PubMed  CAS  Google Scholar 

  163. Lanes R, Soros A, Flores K, Gunczler P, Carrillo E, Bandel J (2005) Endothelial function, carotid artery intima-media thickness, epicardial adipose tissue, and left ventricular mass and function in growth hormone-deficient adolescents: apparent effects of growth hormone treatment on these parameters. J Clin Endocrinol Metab 90:3978–3982

    PubMed  CAS  Google Scholar 

  164. Toogood A (2005) Safety and efficacy of growth hormone replacement therapy in adults. Expert Opin Drug Saf 4:1069–1082

    PubMed  CAS  Google Scholar 

  165. Waterhouse M, Monson JP (2005) Safety aspects of growth hormone replacement. Front Horm Res 33:209–221

    PubMed  CAS  Google Scholar 

  166. Jeffcoate W (2002) Growth hormone therapy and its relationship to insulin resistance, glucose intolerance and diabetes mellitus: a review of recent evidence. Drug Saf 25:199–212

    PubMed  CAS  Google Scholar 

  167. Monson JP, Bengtsson BA, Abs R, Feldt-Rasmussen U, Wuster C (2000) Can growth hormone therapy cause diabetes? KIMS Strategic Committee. Lancet 355:1728–1729

    PubMed  CAS  Google Scholar 

  168. Yuen KC, Frystyk J, White DK, Twickler TB, Koppeschaar HP, Harris PE et al (2005) Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency. Clin Endocrinol (Oxf) 63:428–436

    CAS  Google Scholar 

  169. Frajese G, Drake WM, Loureiro RA, Evanson J, Coyte D, Wood DF et al (2001) Hypothalamo-pituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy. J Clin Endocrinol Metab 86:5172–5175

    PubMed  CAS  Google Scholar 

  170. Chung TT, Drake WM, Evanson J, Walker D, Plowman PN, Chew SL et al (2005) Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement. Clin Endocrinol (Oxf) 63:274–279

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine II, Klinikum der Ludwig-Maximilians-Universität München, Standort Grosshadern, Marchioninistr. 15, Munich, 81377, Germany

    Christoph J. Auernhammer & George Vlotides

  2. Division of Endocrinology, Cedars-Sinai Research Institute, University of California School of Medicine, Los Angeles, CA, 90048, USA

    George Vlotides

Authors
  1. Christoph J. Auernhammer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George Vlotides
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christoph J. Auernhammer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Auernhammer, C.J., Vlotides, G. Anterior pituitary hormone replacement therapy—a clinical review. Pituitary 10, 1–15 (2007). https://doi.org/10.1007/s11102-007-0001-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-007-0001-6

Keywords

Search

Navigation